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Purpose: To develop a oral controlled matrix drug delivery system for a highly water soluble drug, 
diltiazem HCl, and investigate its drug release mechanism.  
Method: Diltiazem HCl was chosen because of its high water solubility. Tablets containing the drug 
were prepared by direct compression method using different matrix ratios of ethyl cellulose (EC) and 
hydroxypropyl methylcellulose (HPMC). The formulations were evaluated in vitro for their dissolution 
characteristics over a period of 8 h. Drug release was analysed according to various release kinetic 
models.  
Results: The results showed that these polymers slowed down the release of diltiazem HCl from the 
matrices. In the presence of EC, increasing the concentration of HPMC decreased the release rate of 
diltiazem. Furthermore, incorporation of EC in tablets with HPMC as the matrix was found to control 
drug release. Kinetic analysis showed that drug release from three of the formulations was adequately 
described by zero order model.  
Conclusion: The formulations developed could potentially be used for controlled delivery of highly 
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INTRODUCTION 
 
Oral ingestion has long been the most 
convenient and commonly employed route of 
drug delivery due to ease of administration, 
high patient compliance, least sterility 
constraints and flexibility in the design of 
dosage form. Hydrophilic polymers are 
becoming increasingly popular in the 
formulation of oral controlled release tablets. 
As the dissolution medium or biological fluid 
penetrates the dosage form, the polymer 
material swells and drug molecules begin to 
move out of the system by diffusion at a rate 
determined by the nature and composition of 
the polymer as well as formulation technology 
[1]. Cellulose ethers, especially hydroxyl-
propyl methylcellulose (HPMC), are 
frequently used as the basis for sustained 
release hydrophilic matrix tablets. Despite 
studies in the 1960s describing their uses 
[2,3], their characterization and performance 
have been more extensively quantified only 
recently. Their properties as gelling agents 
are very important in the formulation because 
they are responsible for the formation, by 
hydration, of a diffusion and erosion-resistant 
gel layer which is able to control drug release 
[4]. On the other hand, hydrophobic materials 
have also been employed as matrix carriers 
for sustained release solid dosage forms 
[5,6].  
 
Ethyl cellulose (EC) is a non-toxic, stable, 
compressible, inert, hydrophobic polymer that 
has been widely used to prepare 
pharmaceutical dosage forms. The properties 
of ethyl cellulose sustained release products, 
including film coated tablets [7], microspheres 
[8,9], microcapsules [10] and matrix tablets 
for both soluble and poorly soluble drugs [11] 
have been reported. The combination of ethyl 
cellulose and a hydrophilic component such 
as HPMC offers a flexible system to tailor the 
drug release by changing the viscosity, 
substitution type and concentration of HPMC 
[12]. In general, designing controlled release 
drug delivery systems for providing 12 or 24 h 
zero order release kinetics, especially for 
highly water-soluble agents, is often difficult 
and unsuccessful. This shortfall in delivery 
system design may be attributed to three 
factors: (a) the high water solubility of the 
drug results in a burst effect; (b) the lack of 
proper control over time-dependent 
processes of polymer relaxation and 
disentanglement in relation to drug 
dissolution and diffusion; and (c) 
compensation for increase in the diffusional 
path length with time is not easily achievable 
[13]. For drugs with high water solubility, 
hydrophobic polymers are suitable, along 
with a hydrophilic matrix, for developing 
sustained release dosage forms. 
Hydrophobic polymers provide several 
advantages, ranging from good stability at 
varying pH values and moisture levels to 
well-established safe applications.  
 
Diltiazem HCl, an orally active calcium 
channel blocking agent, is used in the 
treatment of angina pectoris, hypertension 
and arrhythmia. It is highly water-soluble 
drug, and is rapidly and almost completely 
(60-70%) absorbed from GIT following oral 
administration, but undergoes extensive 
hepatic metabolism. The biological half-life of 
the drug is 3.5 ± 1.2 h. It is typically 
administered three or four times daily, in the 
form of conventional tablets [14]. To minimise 
frequency of administration and the peak-to-
trough oscillation of the blood concentration 
of such a typically water-soluble, diltiazem 
HCl was selected as a suitable candidate for 
this study [15]. Consequently, this work 
sought to develop a sustained-release 
diltiazem hydrochloride system, employing 
hydrophilic (HPMC) and hydrophobic (EC) 
polymers either alone or as a blend. Possible 
mechanisms of the steady-state release 






Diltiazem hydrochloride and ethylcellulose 
(20cps) were received as gifts from Aria 
Pharmaceutical Company, Tehran, Iran. 
HPMC K4M was also a gift from Colorcon, 
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UK While magnesium stearate was 
purchased from Merck Company,,Germany. 
 
Formulation and preparation of matrices 
 
In all formulations, 90 mg of diltiazem 
hydrochloride per tablet was employed and 
the formulations were prepared according to 
the composition shown in Table 1. The drug 
and polymers in their specified ratios were 
simultaneously blended in a laboratory-scale 
Z-shape blender for 15 min. The resulting 
powders were mixed with magnesium 
stearate for 5 min, following which tablets 
were prepared from the blends by direct 
compression on a single punch tablet 
compression machine (Korsch, Germany) 
using flat-faced punches with a diameter of 
0.9 cm. The compression force was adjusted 
to achieve maximum hardness.  
 
Table1: Composition of 90 mg diltiazem tablet 
formulations 




































































           *Formulations code 
 
Determination of hardness of matrix 
tablets  
 
The hardness of the tablets were measured 
using a hardness tester (Erweka TBH-30, 
Germany) 24h after compaction. Ten (10) 
randomly selected tablets per batch were 
measured and the mean taken. 
 
Determination of tablet friability 
 
The friability of the tablets was determined 
using 10 tablets from each formulation, with a 
friabilator (Erweka TAR-20 Germany) at a 
speed of 25 rpm for 4 min. The tablets were 
weighed before and after the friability test, 





Ten randomly selected tablets from each 
formulation were weighed and powdered. 
The quantity of powder equivalent to 90 mg 
of diltiazem hydrochloride was transferred 
into a 100 ml volumetric flask and extracted 
with distilled water. A quantity (1 ml) of the 
filtered solution was diluted to 50 ml with 
distilled water and absorbance was 
measured at 236 nm (Spectronic Genesys 2, 
USA). Each measurement was carried out in 
triplicate and the mean taken. Drug 
concentration was calculated from a 
calibration curve based on a standard 




In vitro dissolution studies were carried out 
using a tablet dissolution tester (Erweka, DT 
800 Germany). The USP basket method I 
was used. Rotation speed was 100 rpm and 
the dissolution medium was distilled water 
(900 ml) maintained at 37 ± 0.5 
o
C. Drug 
release was monitored by UV 
spectrophotometry (Spectronic Genesys 2, 
USA) at a wavelength of 236 nm. The test 
was carried out in triplicate and the results 
expressed as mean ± standard deviation 
(SD). 
 
Analysis of drug release kinetics 
 
The release data were analyzed with the 
following release models: zero order (Eq. 1), 
first order (Eq. 2), Higuchi (Eq. 3), and 
Peppas and Korsemayer (Eq. 4). 
 
Qt = k0 t     ……………………. (1) 
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Ln Qt = ln Q0 - k1t   …….…………….. (2) 
 
Qt = kH t
1/2     ………………………………………… ..   
(3) 
 
 Mt / M∞= Kt
n
  …………………….……. (4 )
  
 
Where Qt is the amount of drug released in 
time t, Q0 is the initial amount of drug in the 
tablet, Mt corresponds to the amount of drug 
released in time t, M∞ is the total amount of 
drug that must be released at infinite time, K 
is a constant and n is the release exponent 
indicating the type of drug release 
mechanism. If n approaches 1, the release 
mechanism is zero order; on the other hand, 
if 0.5 < n < 1, non-Fickian transport is the 
case. The drug release data obtained were 
subjected to the above drug release models 
in order to establish their release mechanism 
and kinetics. Criteria for selecting the most 
appropriate model were based on best fit and 




A one–way ANOVA with a Tukey’s post hoc 
test was used to analyze the dissolution data 
obtained for each batch of formulation in 
order to compare the rate of drug release 
from the matrix tablets. The confidence limit 




Table 2 indicates the results of the 
physicochemical tests (hardness, friability 
and assay) performed on the tablet 
formulations. The data show that hardness 
ranged from 18.14 to 141.74N while friability 
ranged from 0.16 to 1.61 %.  
 
The results of the dissolution studies, shown 
in Figs 1 and 2, indicate that while 
formulations F1, F2 and F3 released 36.7, 
73.7 and 10.7 % of diltiazem, respectively, 
after 2 h and 79.7, 100.0 and 69.7 % of drug, 
respectively, after 8 h, formulations F4, F5 
and F6 released 68.3, 96.3 and 62.7 % of 
diltiazem, respectively, at the end of 2 h, and  
 











F1 121.72 ± 2.25 0.32 99.38 ± 0.15 
F2 55.10 ±1.32 0.92 98.27 ± 0.19 
F3 56.70 ±1.28 0.89 97.85 ± 0.22 
F4 34.72 ±0.48 1.31 98.72 ± 0.18 
F5 26.77 ±0.58 1.48 99.19 ± 0.09 
F6 123.82 ± 2.66 0.31 98.33 ± 0.18 
F7 112.70 ± 2.16 0.42 98.37 ± 0.17 
F8 141.74 ± 1.85 0.16 98.78 ± 0.14 
F9 132.18 ± 1.74 0.27 97.90 ± 0.25 
F10 29.52 ±0.56 1.43 98.61 ± 0.17 
F11 21.52 ± 0.41 1.51 97.54 ± 0.09 
F12 18.14 ± 0.35 1.61 97.35 ± 0.13 
F13 85.24 ± 1.24 0.51 99.12 ± 0.15 
F14 83.78 ± 0.85 0.52 98.16 ± 0.23 
F15 44.74 ± 0.82 1.04 97.79 ± 0.19 
*Formulations code; 
a
Mean ± SD, n= 10; 
b
Mean ± 

























Figure 1: In vitro release (mean ± SD) of diltiazem 
HCl from F1(◊), F2(■), F3(▲),F4(×), F5(∆) and 
F6(○) formulations.   
 
89.0, 100.0 and 100.0 % of drug, 
respectively, after 8 h (see Fig 1). The 
dissolution profiles of diltiazem tablets 
containing blends of HPMC and EC are 
shown in Fig 2. The tablets with a constant 
amount of HPMC but varying ratios of EC 
(F1, F7 and F9) released 79.7, 94.0 and 76.0 
% of diltiazem, respectively, after 8 h.
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Figure 2: In vitro release (mean ± SD) of diltiazem HCl from F7(◊), F8(■), F9(▲), F10(×), F11(○),F12(●), 
F13(∆), F14(+) and F15(□) formulations  
 
 
Table 3: Computed kinetic release parameters for diltiazem formulations 
F*: code of formulations; K0, the zero order release rate constant, K1, the first order release rate constant; K 
H, the Higuchi’s release rate constant; KK p, Korsmeyer-Peppas release constant, n, diffusional exponent   
 
The results of the analysis of drug release 
kinetics based on various models are shown 
in Table 3. It is evident that formulations F3, 
F7 and F15 followed a zero-order release 
pattern while formulations F10, F11 and F14 
formulations followed first order release, with 







The present study was carried out to develop 
oral controlled release tablet dosage form for 
highly water-soluble drugs such as diltiazem 
hydrochloride using a blend of HPMC and EC 
as the matrix. 































F1 0.0014 0.9487 -0.0033 0.9886 0.0402 0.9902 0.0247 0.5802 0.9974 
F2 0.0028 0.9832 -0.0268 0.6888 0.0663 0.9971 0.0267 0.6404 0.9995 
F3 0.0015 0.9367 -0.0024 0.8664 0.0393 0.8554 0.0008 1.0432 0.7728 
F6 0.0012 0.7650 -0.0037 0.9029 0.0349 0.8833 0.0263 0.6748 0.9648 
F7 0.0017 0.9892 -0.0078 0.7128 0.0485 0.9727 0.0223 0.5915 0.9801 
F8 0.0013 0.9056 -0.0031 0.9637 0.0380 0.9727 0.0243 0.6039 0.9884 
F9 0.0014 0.9857 -0.0026 0.9908 0.0391 0.9973 0.0078 0.7442 0.9967 
F10 0.0010 0.9749 -0.0014 0.9843 0.0291 0.9776 0.0001 1.4966 0.9367 
F11 0.0011 0.9881 -0.0016 0.9984 0.0306 0.9965 0.0014 0.9803 0.9797 
F12 0.0011 0.9768 -0.0017 0.9939 0.0307 0.9921 0.0080 0.6944 0.9915 
F13 0.0013 0.8827 -0.0031 0.9600 0.0375 0.9621 0.0237 0.6200 0.9979 
F14 0.0023 0.8687 -0.0061 0.9779 0.0551 0.9473 0.0068 0.9589 0.9727 
F15 0.0020 0.9931 -0.0088 0.8760 0.0541 0.9859 0.0354 0.5187 0.9922 
Enayatifard et al 
Trop J Pharm Res, October 2009; 8 (5):  430 
As shown in Table 2, the drug content of all 
formulations was between 97.4 and 99.4 %, 
indicating the presence of an acceptable 
amount of drug in the formulations. 
Furthermore, all the formulations showed 
acceptable hardness and friability. 
 
In vitro drug release  
 
The in vitro drug release data obtained over a 
period of 8 h indicate that for F1, F2 and F3 
formulations, the release rate decreased as 
the concentration of HPMC increased. The 
results of this study are consistent with 
findings in a previous report by Pham and 
Kee [16], which showed that the presence of 
a highly water-soluble compound, 
fluorescine, in a HPMC matrix generates an 
additional osmotic gradient, thereby resulting 
in a faster rate of polymer swelling and a 
large increase in gel thickness. In the 
presence of a solvent, the mobility of the 
polymer chains is enhanced, resulting in a 
gradual transformation of a glassy matrix to a 
rubbery swollen gel. At higher polymer 
loading, the viscosity of the gel matrix is 
increased which results in a decrease in the 
effective diffusion coefficient of the drug [17]. 
Wan et al have also reported that other 
factors that may contribute to differences in 
drug dissolution profile as a function of 
changes in total polymer concentration 
include differences in water penetration rate, 
water absorption capacity and polymer 
swelling [18].  
 
Incorporation of varying concentrations of 
ethyl cellulose (F4, F5 and F6) controlled 
drug release. This may be attributed to 
decreased penetration of the solvent 
molecules in the presence of the hydrophobic 
polymer, leading to reduced diffusion of the 
drug from the matrix. According to 
penetration theory, when a matrix is 
composed of a water-soluble drug and a 
water-insoluble polymer, drug release occurs 
by dissolution of the active ingredient through 
capillaries composed of interconnecting drug 
particle clusters and the pore network [19,20]. 
As drug release continues, the 
interconnecting clusters increase the pore 
network through which interior drug clusters 
can diffuse with more ethyl cellulose particles 
present, and the theory predicts that fewer 
clusters of soluble drug substance are 
formed. Furthermore, the presence of finite 
drug clusters is more statistically plausible. 
The resulting pore network becomes less 
extensive and more tortuous resulting in 
slower drug release. In tablets which were 
prepared with the same amount of HPMC but 
varying concentration of EC (F1, F7 and F9), 
the release rate of diltiazem decreased 
significantly (P = 0.023) with increasing EC 
content. Although, incorporation of EC 
controlled drug release to some extent, the 
inclusion of this polymer in formulation F7 
increased the release of the drug. The reason 
might be that its large hydrophobic molecules 
imposed a discontinuity in the gel-structure 
leading to formation of a weaker barrier than 
the HPMC gel alone [21].  
 
During the formulation development process, 
formulation F2 was modified by the addition 
of EC in varying concentrations to yield F8 
and F14. F2, F8 and F14 released 100.0, 
78.7 and 93.3% of diltiazem, respectively, 
within 8 hours. This decrease was significant 
for F8 and F14 (P ≤ 0.001). Drug release 
(over 8 h) from EC matrix tablets with varying 
concentrations of HPMC (F5, F9 and F11) 
was 100.0, 76.0 and 53.3%, respectively. 
Thus there were significant differences in 
drug release between these formulations (P ≤ 
0.001). It seems that increasing the 
concentration of HPMC decreased the 
release rate of diltiazem, due to the fact that 
HPMC forms a strong viscous gel on contact 
with aqueous media with the gel controlling 
delivery of the highly water-soluble drug. 
Usually, water-soluble drugs are released 
primarily by diffusion of dissolved drug 
molecules across the gel layer [22]. The 
extent of polymer swelling and the hydration 
of the microstructure formed within the gel 
layer vary with the degree of polymer 
interaction with hydrating media.  
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Drug release kinetics 
 
When the release data were subjected to 
first-order, Higuchi, Korsmeyer et al and zero 
order models, F10, F11 and F14 formulations 
showed linearity with regression values 
between 0.9779 and 0.9984 for first order. 
Release of drug from a matrix tablet 
containing hydrophilic polymers generally 
involves factors of diffusion. The relaxation 
and swelling characteristics of HPMC 
matrices may influence drug release kinetics. 
These matrices have been shown to expand 
predominantly in an axial direction. Drug 
release from swelling matrices is dependent 
on the diffusion and relaxation behavior of the 
dosage form. The diffusional release is by 
molecular diffusion down a chemical potential 
gradient whereas relaxational release is by 
drug transport mechanisms associated with 
stresses and state transitions involved in the 
swelling of the hydrophilic polymer. The 
swelling of the polymer would alter the drug 
concentration gradient in the gel layer [23]. 
As the gradient varies, the drug is released, 
and the distance for diffusion increases. This 
could explain why the drug diffuses at a 
comparatively slower rate as the distance for 
diffusion increases, which is governed by 
square-root or Higuchi kinetics. To confirm 
the release mechanism, the data were fitted 
into Korsmeyer et al model. F1, F2, F6 and 
F13 showed good linearity (r
2
 = 0.9648 to 
0.9995), with the slope or exponential value 
(n) ranging from 0.5802 to 0.6748, indicating 
a coupling of diffusion and erosion 
mechanisms – so-called anomalous diffusion. 
When plotted according to Korsmeyer et al 
model, F9 also showed high linearity (r
2
 = 
0.9967), with a comparatively high slope (n) 
value of 0.7442 This n value, however, 
appears to indicate that diffusion is the 
dominant mechanism of drug release for this 
formulation. The in vitro release profile of 
drug from formulation F9 could be best 
expressed by Higuchi’s equation, as the plot 
showed high linearity (r
2
 = 0.9973).  The drug 
release kinetics of formulations F3, F7 and 
F15 fitted best to the zero order model. In 
these formulations the amount of HPMC 




The findings of the present study 
demonstrate that HPMC and EC could slow 
down the release profile of diltiazem HCl from 
their matrices. Incorporation of EC in HPMC 
matrix tablets was found to control drug 
release. Release kinetics analysis showed 
that drug release from three formulations was 
adequately described by zero-order equation. 
This approach to formulation development 
may be suitable for controlled delivery of 
highly soluble drugs such as diltiazem HCl. 
 
ACKNOWLEDGMENT    
 
This work was supported by a grant from the 
Research Council of the Mazandaran 
University of Medical Sciences, Iran. We 
would like to thank Dr. Khorrami (Targolshimi 
Co.) for donating the HPMC used, and Aria 





1.  Krishnaiah YSR, Karthikeyan RS, Satyanarayana V. 
A three-layer guar gum matrix tablet for oral 
controlled delivery of highly soluble metoprolol 
tartrate. Int. J. Pharm., 2002; 241: 353-366. 
2.  Lapidusa H, Lordi NG. Some factors affecting the 
release of a water – soluble drug from a 
compressed hydrophilic matrix. J. Pharm. Sci., 
1966; 55:  840-843. 
3.  Lapidusa H, Lordi NG. Drug release from compressed 
hydrophilic matrices. J. Pharm. Sci., 1968; 57: 
1292-1301. 
4.  Vasques MJ, Perez- Marcus B, Gomez- Amora JL, 
Martinez- Pacheo R, Souto C, Concheiro A. 
Influence of technological variables on release 
of drugs, from hydrophilic matrices. Drug Dev. 
Ind. Pharm., 1992; 18: 1355-1375. 
5.  Thies R, Kleinebudde P. Melt pelletisation of a 
hygroscopic drug in a high – shear mixer. Part 
1. Influence of process variables. Int. J. 
Pharm., 1999; 188: 131- 143. 
6.  Voinovich D, Moneghini M, Perissutti B, Filipovic-
Gesic J, Grabnar I. Preparation in high shear 
mixer of sustained –release pellets by melt 
pelletisation. Int. J. Pharm., 2000; 203: 235-
244. 
Enayatifard et al 
Trop J Pharm Res, October 2009; 8 (5):  432 
7.  Rowe RC. Molecular weight dependence of the 
properties of ethyl cellulose and hydroxypropyl 
methylcellulose films. Int. J. Pharm., 1992; 88: 
405-408.                      
8.  Akbuga J. Furosemide-loaded ethyl cellulose 
microspheres prepared by spherical 
crystallization technique: morphology and 
release characterization. Int. J. Pharm., 1991; 
76: 193-198.                     
9.  Eldrige JH, Hommond CJ, Meulbroek JA, Staas JK, 
Gilley RM, Tice TR. Controlled vaccine release 
in the gut- associated lymphoid tissues. Part I. 
Orally administered biodegradable micro-
spheres target the peyer’s patches. J. Control. 
Rel., 1990; 11:       205-214                        . 
10. Janselijak I., Nicolaidou CF, Nixon JR. Dissolution 
from tablets prepared using ethylcellulose 
microcapsules J. Pharm. Pharmacol., 1977; 
29: 169-172. 
11. Shaikh NA, Abidi SE, Block LH. Evaluation of ethyl 
cellulose as  a matrix for prolonged release 
formulations. Part 1. Water-soluble drugs- 
acetaminophen theophylline. Drug Dev. Ind. 
Pharm., 1987a; 13: 1345-1369.  
12. Verhoeven E, Vervaet C., Remon JP. Xanthan gum 
to tailor drug release of sustained release ethyl 
cellulose mini-matrices prepared via hot-melt 
extrusion: in vitro and in  vivo evaluation. 
Eur.J. Pharm. Biopharm., 2006; 63: 320-330. 
13. Pillay V, Fassihi R. A novel approach for constant 
rate delivery of highly soluble bioactives from a 
simple monolithic system. J. Cont. Rel. ,2000; 
67: 67-78.       
14. Kerins DM, Robertson RM, Robertson D. Therapy of 
Hypertension. In: Harman JG, Limbird LE 
(eds). Goodman and Gilman’s The 
Pharmacological Basis of Therapeutics, ed 10, 
New York, USA: Mc Graw-Hill, 2001, pp 859-
860.                                  
15. Shirwaikar AA, Srintha A. Sustained release be-
layered tablets of diltiazem hydrochloride using 
insoluble matrix system. Indian J. Pharm. Sci., 
2004; 66, 4: 433-437. 
16. Pham AT, Lee PI. Probing the mechanisms of drug 
release from hydroxypropylmethylcellulose 
matrices. Pharm. Res., 1994; 11: 1379- 1384. 
17. Skoug JW, Mikelsons MV, Vigneron CN, Stemm NL. 
Qualitative evaluation of the mechanism of 
release of matrix sustained release dosage 
forms by measurement of  polymer release. J. 
Cont. Rel., 1993; 27: 227-245. 
18. Wan LSC, Heng PWS, Wong LF. Relationship 
between swelling and drug release in a 
hydrophilic matrix. Drug Dev. Ind., Pharm., 
1993; 19: 1201-1210. 
19.  Holman LE, Leuenberger H. The relationship 
between solid fraction and mechanical            
 properties of compacts – the Percolation 
Theory model Approach. Int. J. Pharm.,            
 1988; 46: 35-44.  
20.  Leuenberger H, Rohera BD, Haas C. Percolation 
Theory – a novel approach to solid dosage 
form design. Int. J. Pharm., 1987; 38: 109-115. 
21.  Ahrabi SF, Madsen G, Dyrstad K, Sande SA, 
Graffner C. Development of pectin matrix         
 tablets for colonic delivery of model drug 
Ropivacaine. Eur. J. Pharm. Sci., 2000;           
 10: 43-52.  
22.  Alderman DA. A review of cellulose ethers in 
hydrophilic matrices oral controlled-release 
dosage forms. Int. J. Pharm. Tech. Prod. Man., 
1984; 5: 1-9. 
23.  Ford JL. Thermal analysis of hydroxypropyl 
methylcellulose and methylcellulose:               
 powders, gels and matrix tablet. Int. J. 
Pharm., 1999; 179: 209-228. 
 
 
 
